27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cognitive stimulation therapy for people with dementia has effectiveness advantages over, and may be more cost-effective than, treatment as usual. 1 key finding →
Design: randomized controlled trial Participants: 91 Evidence: high
Full summary, score breakdown and related studies → Original source
Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. 4 key findings →
Participants: 16 Evidence: high
Full summary, score breakdown and related studies → Original source
The incidence of MCR is high in older adults. 2 key findings →
Design: cohort study Participants: 3,128 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. 3 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source
Current evidence shows that plasma p-tau217 is a sensitive maker of the clinical manifestation and progression of Alzheimer's disease and of pathological changes associated with this condition, including amyloid accumulation, tau burden, brain atrophy and physical degradation. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
There is a need for blood biomarkers to detect individuals at different Alzheimer's disease (AD) stages because obtaining cerebrospinal fluid-based biomarkers is invasive and costly. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Among the individual plasma p-tau variants, p-tau217 consistently outperformed p-tau181 and p-tau231. 4 key findings →
Design: longitudinal study Participants: 352 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognition ranged from high to early cognitive decline (median Mini-Mental State Examination [MMSE] score = 26). 5 key findings →
Design: longitudinal study Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 143 iRBD participants (110 male, 67.7 ± 8.0 years) were included. 5 key findings →
Design: cohort study Participants: 2,004 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Nine proteins (amyloid-beta 42 (Aβ42), beta-secretase 1 (BACE1), glial fibrillary acidic protein (GFAP), pTau181, pTau231, pTau217, t0tal tau (MAPT), neurofilament light (NfL) and acetylcholinesterase (AChE)) robustly differed between carriers and non-carriers cross-sectionally. 5 key findings →
Design: cohort study Participants: 113 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We included 401 individuals (61±9 years, 42% female, MMSE 28 ± 2, vascular comorbidities 8%-19%). 5 key findings →
Design: cohort study Participants: 401 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma amyloid-β peptide concentration has recently been shown to have high accuracy to predict amyloid-β plaque burden in the brain. 2 key findings →
Design: longitudinal study Participants: 15 Evidence: moderate
Full summary, score breakdown and related studies → Original source
IICV was associated with concurrent/baseline performance on several outcomes but did not modify associations between age and cognitive decline. 4 key findings →
Design: longitudinal study Participants: 235 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Seventy-six articles met the inclusion criteria for systematic review. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Bisecting N-acetylglucosamine correlated with tau levels (p < 0.0001). 4 key findings →
Design: retrospective cohort Participants: 233 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. 5 key findings →
Design: cohort study Participants: 366 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Gait speed for participants who worsened in CDR score during follow-up was slower at most examinations. 4 key findings →
Design: cohort study Participants: 287 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q-assessed anxiety, apathy, and nighttime behavior. 3 key findings →
Design: cohort study Participants: 784 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher WMH volume was associated with older age, lower CSF amyloid-β levels, hypertension, and smoking history (all p ≤ 0.001), as well as cognitive status (MCI, p < 0.001; dementia, p = 0.008), but not with CSF tau levels. 5 key findings →
Design: longitudinal study Participants: 1,803 Evidence: moderate
Full summary, score breakdown and related studies → Original source
To the best of our knowledge, this will be the first systematic review and meta-analysis of narrowly defined CCT across clinical populations with depression. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
The slow progression of Alzheimer's disease (AD) poses a challenge for the quantification of early disease-driven cognitive decline. 2 key findings →
Design: longitudinal study Participants: 152 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The CDR+NACC FTLD global score interacted with time on battery percentage such that participants with prodromal or symptomatic FTLD demonstrated less change in battery percentage throughout the day (a proxy for less smartphone use) than clinically normal participants (P<.001 in both cases). 4 key findings →
Design: longitudinal study Participants: 94 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Targeted analysis of 20 SNPs that were reported to be associated with ADRD revealed that six were significantly associated with dual-disease outcomes, specifically congestive heart failure and cancer. 4 key findings →
Design: longitudinal study Participants: 1,177 Evidence: moderate
Full summary, score breakdown and related studies → Original source
First, we mapped SVs across 81 AD risk loci and discovered 22 SVs in linkage disequilibrium (LD) with GWAS lead variants and directly associated with the phenotypes tested. 5 key findings →
Design: cohort study Participants: 1,088 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A one standard deviation increase in AD-PGS was associated with an accelerated time to dementia diagnosis by 4.8 months. 5 key findings →
Design: prospective cohort Participants: 7,039 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →